Fig. 4: Effects of dexamethasone on the hearing loss in DC-targeted Cx26-null mice.

A Schematic of the experimental workflow, Cx26f/f; Fgfr3-CreER mice were injected with TMX and then treated with dexamethasone 5 mg/kg of body weight for five days. B, C Cx26 immunolabeling (red) in the apical of the control group. D, E Cx26 immunolabeling (red) in the apical of the targeted DCs Cx26-null group. The white arrowheads in panel (D) indicate that Cx26 of DCs was successfully knocked out. F ABR thresholds were analyzed indifferent group at P18. n = 5 mice in each group, *P < 0.05. Scale in panel (B) represents for 40 μm.